Abcellera Biologics Inc
$ 3.22
6.27%
24 Feb - close price
- Market Cap 906,985,000 USD
- Current Price $ 3.22
- High / Low $ 3.27 / 3.06
- Stock P/E N/A
- Book Value 3.22
- EPS -0.57
- Next Earning Report 2026-02-24
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.10 %
- ROE -0.17 %
- 52 Week High 6.51
- 52 Week Low 1.89
About
AbCellera Biologics Inc. develops an antibody discovery platform. The company is headquartered in Vancouver, Canada.
Analyst Target Price
$9.83
Quarterly Earnings
| Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-02-24 | 2025-11-06 | 2025-08-07 | 2025-05-05 | 2025-02-18 | 2024-11-04 | 2024-08-06 | 2024-05-07 | 2024-02-20 | 2023-11-02 | 2023-08-03 | 2023-05-04 |
| Reported EPS | 0 | -0.19 | -0.12 | -0.15 | -0.12 | -0.17 | -0.13 | -0.14 | -0.17 | -0.1 | -0.11 | -0.14 |
| Estimated EPS | -0.144 | -0.14 | -0.14 | -0.17 | -0.1471 | -0.15 | -0.14 | -0.17 | -0.13 | -0.13 | -0.13 | -0.14 |
| Surprise | 0.144 | -0.05 | 0.02 | 0.02 | 0.0271 | -0.02 | 0.01 | 0.03 | -0.04 | 0.03 | 0.02 | 0 |
| Surprise Percentage | 100% | -35.7143% | 14.2857% | 11.7647% | 18.4228% | -13.3333% | 7.1429% | 17.6471% | -30.7692% | 23.0769% | 15.3846% | 0% |
Next Quarterly Earnings
| Dec 2025 | |
|---|---|
| Reported Date | 2026-02-24 |
| Fiscal Date Ending | 2025-12-31 |
| Estimated EPS | -0.18 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: ABCL
2026-02-23 23:06:55
AbCellera Biologics (ABCL) is preparing to announce its fiscal year earnings, with analysts projecting a 26.0% year-over-year revenue increase to $36.29 million and an EPS of -$0.63. Despite its innovative antibody discovery platform, the company faces significant financial challenges, evidenced by negative operating margins, a low Piotroski F-Score, and an Altman Z-Score indicating distress. Although the stock shows some signs of potential undervaluation (P/S ratio of 25.67, P/B ratio of 0.94) and recent insider buying, overall market sentiment is cautious.
2026-02-23 15:14:12
AbCellera Biologics Inc (ABCL) reported Q4 2025 earnings per share of $-0.19, missing analyst estimates of $-0.16 by 17.3%. The company's revenue for the quarter totaled $35.3 million. Following the announcement, shares of ABCL fell 2.3% in after-hours trading to $3.00.
2026-02-18 07:27:32
Brokerages have given AbCellera Biologics Inc. (NASDAQ:ABCL) an average recommendation of "Hold," based on ratings from six firms with an average 12-month price target of $7.75. Institutional investors own 61.42% of the company, with notable recent increases in holdings from firms like Invesco and new stakes from entities such as the State of Michigan Retirement System. The company, which specializes in antibody discovery using an AI-integrated platform, opened at $3.17, has a market cap of $948.88 million, and trades with a negative PE ratio of -5.56.
2026-02-17 09:57:41
AbCellera Biologics (NASDAQ:ABCL) is projected to announce its Q4 2025 earnings after market close on Tuesday, February 24th, 2026. Analysts expect an EPS loss of ($0.16) and revenue of approximately $6.312 million. The stock recently traded up 5.4% at $3.10, has a market cap of about $928 million, and a consensus "Hold" rating with an average price target of $7.75.
2026-02-14 22:28:28
Wall Street Zen has upgraded AbCellera Biologics (NASDAQ:ABCL) from a "sell" to a "hold" rating, contributing to its current consensus "Hold" rating among analysts, with an average target price of $7.75. The stock saw a 5.4% increase, opening at $3.10, and institutional investors now hold 61.42% of the shares, with several firms recently increasing their stakes. AbCellera Biologics specializes in antibody discovery and development, leveraging AI and various technologies to accelerate drug discovery in partnership with pharmaceutical companies.
2026-02-13 23:27:55
AbCellera Biologics Inc. (ABCL) is presented as a high-risk, high-reward biotechnology investment with a market capitalization of $880.05 million. Despite current unprofitability, negative EPS, and negative free cash flow, analysts show strong confidence with an average target price suggesting a 234% potential upside. The company's innovative antibody discovery approach, strategic partnerships, and investments in its R&D pipeline are highlighted as key growth drivers.
